H.R. 63 · 110th Congress
RU-486 Suspension and Review Act of 2007
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 110th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
BartlettSponsor48 cosponsors · 1 D, 47 R
R
Alexander
MB
R
Blackburn
JAR
Ann Davis
LD
D
Davis
GD
R
Davis
TF
R
Franks
JF
R
Fortenberry
VG
R
Goode
PG
R
Gingrey
WH
R
Herger
PH
R
Hoekstra
SK
R
King
RL
R
Lewis
DM
R
Manzullo
MM
R
Musgrave
CN
R
Norwood
CS
R
Smith
BS
R
Sali
RW
R
Wicker
JW
R
Wilson
JB
R
Boozman
VE
R
Ehlers
RH
R
Hall
DH
R
Hunter
RH
R
Hayes
JH
R
Hensarling
WJ
R
Jones
TM
R
Murphy
JP
R
Pitts
RR
R
Renzi
JS
R
Shimkus
JS
R
Sullivan
TT
R
Tiahrt
LT
R
Terry
PT
R
Tiberi
TM
R
McCotter
LW
R
Westmoreland
TE
R
Everett
RL
R
LaHood
JS
R
Schmidt
SB
R
Bachus
SC
R
Chabot
EW
R
Whitfield
BI
R
Inglis
HR
R
Rogers
MS
R
Souder
DL
R
Lamborn
VF
R
Foxx0 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
RU-486 Suspension and Review Act of 2007 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.
What it does: CRS summary · Introduced in House · Jan 4, 2007
RU-486 Suspension and Review Act of 2007 - Deems the approved application for the drug mifepristone (marketed as Mifeprex, commonly known as RU-486, and used for the chemically induced termination of intrauterine pregnancy) to have been withdrawn.
Deems the drug misoprostol to be misbranded under the Federal Food, Drug, and Cosmetic Act (FFDCA) if it bears labeling providing that the drug may be used for the medical termination of intrauterine pregnancy.
Directs the Comptroller General to review and report on the process by which the Food and Drug Administration (FDA) approved mifepristone. Provides for the reinstatement of the approved application for such drug if the report determines the approval to have been in accordance with FFDCA.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: RU-486 Suspension and Review Act of 2007
Latest action (Feb 2, 2007): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Jan 4, 2007
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.